Thrombocytopenia in the intensive care unit

Journal of Intensive Care Medicine

Volumn 28, Issue 5, 2013, Pages 268-280

  Wang, Helena L ^a   Aguilera, Claudine ^a   Knopf, Kevin B ^a   Chen, Tze Ming Benson ^a   Maslove, David M ^b   Kuschner, Ware G ^b,c  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

critical care; platelet consumption; platelet destruction; platelet sequestration; platelet transfusion; thrombocytopenia

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMPICILLIN; ARGATROBAN; CARBAMAZEPINE; CLOPIDOGREL; CONJUGATED ESTROGEN; DANAPAROID; DESMOPRESSIN; DIPYRIDAMOLE; EPTIFIBATIDE; ETHAMBUTOL; FIBRINOGEN RECEPTOR ANTAGONIST; HALOPERIDOL; HEPARIN; HIRULOG; IBUPROFEN; IRINOTECAN; LEPIRUDIN; LINEZOLID; LOW MOLECULAR WEIGHT HEPARIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; TAMOXIFEN; TICLOPIDINE; UNINDEXED DRUG; VANCOMYCIN; VITAMIN K GROUP; WARFARIN;

CELL DESTRUCTION; DRUG EFFECT; HUMAN; HYPOTHERMIA; INTENSIVE CARE UNIT; LABORATORY TEST; PRIORITY JOURNAL; REVIEW; SEPSIS; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

CRITICAL CARE; PLATELET CONSUMPTION; PLATELET DESTRUCTION; PLATELET SEQUESTRATION; PLATELET TRANSFUSION; THROMBOCYTOPENIA;

HUMANS; INTENSIVE CARE; PLATELET ACTIVATION; PLATELET TRANSFUSION; THROMBOCYTOPENIA;

EID: 84883400117     PISSN: 08850666     EISSN: 15251489     Source Type: Journal    
DOI: 10.1177/0885066611431551     Document Type: Review

References (115)

1. Crowther MA, Cook DJ, Meade MO, et al. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care. 2005 ; 20 (4). 348-353
2. Stephan F, Hollande J, Richard O, Cheffi A, Maier-Redelsperger M, Flahault A. Thrombocytopenia in a surgical ICU. Chest. 1999 ; 115 (5). 1363-1370
3. Hanes SD, Quarles DA, Boucher BA. Incidence and risk factors of thrombocytopenia in critically ill trauma patients. Ann Pharmacother. 1997 ; 31 (3). 285-289
4. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010 ; 362 (7). 600-613
5. Trowbridge EA, Martin JF, Slater DN. Evidence for a theory of physical fragmentation of megakaryocytes, implying that all platelets are produced in the pulmonary circulation. Thromb Res. 1982 ; 28 (4). 461-475
6. Brecher G, Cronkite EP. Morphology and enumeration of human blood platelets. J Appl Physiol. 1950 ; 3 (6). 365-377
7. Bessman JD, Williams LJ, Gilmer PR. Mean platelet volume. The inverse relation of platelet size and count in normal subjects, and an artifact of other particles. Am J Clin Pathol. 1981 ; 76 (3). 289-293
8. Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol. 1999 ; 106 (2). 345-356
9. Alberio L, Friese P, Clemetson KJ, Dale GL. Collagen response and glycoprotein VI function decline progressively as canine platelets age in vivo. Thromb Haemost. 2002 ; 88 (3). 510-516
10. Peng J, Friese P, Heilmann E, George JN, Burstein SA, Dale GL. Aged platelets have an impaired response to thrombin as quantitated by P-selectin expression. Blood. 1994 ; 83 (1). 161-166
11. Jackson SP. The growing complexity of platelet aggregation. Blood. 2007 ; 109 (12). 5087-5095
12. Stanworth SJ, Denton K, Monteath J, Patton WN. Automated counting of platelets on the Bayer ADVIA 120 analyser. Clin Lab Haematol. 1999 ; 21 (2). 113-117
13. Kunz D, Kunz WS, Scott CS, Gressner AM. Automated CD61 immunoplatelet analysis of thrombocytopenic samples. Br J Haematol. 2001 ; 112 (3). 584-592
14. Fiorin F, Steffan A, Pradella P, Bizzaro N, Potenza R, De Angelis V. IgG platelet antibodies in EDTA-dependent pseudothrombocytopenia bind to platelet membrane glycoprotein IIb. Am J Clin Pathol. 1998 ; 110 (2). 178-183
15. Bartels PC, Schoorl M, Lombarts AJ. Screening for EDTA-dependent deviations in platelet counts and abnormalities in platelet distribution histograms in pseudothrombocytopenia. Scand J Clin Lab Invest. 1997 ; 57 (7). 629-636
16. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost. 1990 ; 16 (1). 1-20
17. Hayward CP, Pai M, Liu Y, et al. Diagnostic utility of light transmission platelet aggregometry: results from a prospective study of individuals referred for bleeding disorder assessments. J Thromb Haemost. 2009 ; 7 (4). 676-684
18. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation. 1999 ; 99 (5). 620-625
19. Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer - PFA-100. Semin Thromb Hemost. 1995 ; 21 (suppl 2). 106-112
20. Steiner RW, Coggins C, Carvalho AC. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol. 1979 ; 7 (2). 107-117
21. Di Minno G, Martinez J, McKean ML, De La Rosa J, Burke JF, Murphy S. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med. 1985 ; 79 (5). 552-559
22. Mhawech P, Saleem A. Inherited giant platelet disorders. Classification and literature review. Am J Clin Pathol. 2000 ; 113 (2). 176-190
23. Marone G, Albini F, di Martino L, Quattrin S, Poto S, Condorelli M. The Wiskott-Aldrich syndrome: studies of platelets, basophils and polymorphonuclear leucocytes. Br J Haematol. 1986 ; 62 (4). 737-745
24. Phillips DR, Agin PP. Platelet membrane defects in Glanzmann's thrombasthenia. Evidence for decreased amounts of two major glycoproteins. J Clin Invest. 1977 ; 60 (3). 535-545
25. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005 ; 128 (3). 275-290
26. Livio M, Gotti E, Marchesi D, Mecca G, Remuzzi G, de Gaetano G. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet. 1982 ; 2 (8306). 1013-1015
27. Zeigler ZR, Megaludis A, Fraley DS. Desmopressin (d-DAVP) effects on platelet rheology and von Willebrand factor activities in uremia. Am J Hematol. 1992 ; 39 (2). 90-95
28. Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med. 1983 ; 308 (1). 8-12
29. Janson PA, Jubelirer SJ, Weinstein MJ, Deykin D. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med. 1980 ; 303 (23). 1318-1322
30. Livio M, Mannucci PM, Vigano G, et al. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med. 1986 ; 315 (12). 731-735
31. Vigano G, Gaspari F, Locatelli M, Pusineri F, Bonati M, Remuzzi G. Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. Kidney Int. 1988 ; 34 (6). 853-858
32. Vigano G, Zoja C, Corna D, et al. 17 beta-estradiol is the most active component of the conjugated estrogen mixture active on uremic bleeding by a receptor mechanism. J Pharmacol Exp Ther. 1990 ; 252 (1). 344-348
33. Leslie SD, Toy PT. Laboratory hemostatic abnormalities in massively transfused patients given red blood cells and crystalloid. Am J Clin Pathol. 1991 ; 96 (6). 770-773
34. Levi M. Current understanding of disseminated intravascular coagulation. Br J Haematol. 2004 ; 124 (5). 567-576
35. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009 ; 145 (1). 24-33
36. Mitra D, Jaffe EA, Weksler B, Hajjar KA, Soderland C, Laurence J. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood. 1997 ; 89 (4). 1224-1234
37. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982 ; 307 (23). 1432-1435
38. Plaimauer B, Zimmermann K, Volkel D, et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood. 2002 ; 100 (10). 3626-3632
39. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991 ; 325 (6). 393-397
40. Stone JH. HELLP syndrome: hemolysis, elevated liver enzymes, and low platelets. JAMA. 1998 ; 280 (6). 559-562
41. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009 ; 113 (26). 6511-6521
42. Wright JF, Blanchette VS, Wang H, et al. Characterization of platelet-reactive antibodies in children with varicella-associated acute immune thrombocytopenic purpura (ITP). Br J Haematol. 1996 ; 95 (1). 145-152
43. Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009 ; 146 (6). 585-596
44. Cook D, Crowther M, Meade M, et al. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med. 2005 ; 33 (7). 1565-1571
45. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001 ; 344 (17). 1286-1292
46. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003 ; 101 (8). 2955-2959
47. Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia: diagnosis and management update. Postgrad Med J. 2007 ; 83 (983). 575-582
48. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest. 2005 ; 127 (5). 1857-1861
49. Warkentin TE. Heparin-induced thrombocytopenia. Curr Hematol Rep. 2002 ; 1 (1). 63-72
50. Warkentin TE. Think of HIT. Hematology Am Soc Hematol Educ Program. 2006;2006(1) ;: 408-414
51. Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. Semin Thromb Hemost. 2004 ; 30 (3). 273-283
52. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest. 2005 ; 127 (2 suppl). 35S - 45S
53. Warkentin TE. Heparin-induced thrombocytopenia: diagnosis and management. Circulation. 2004 ; 110 (18). e454 - e458
54. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation. 1999 ; 100 (6). 587-593
55. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999 ; 99 (1). 73-80
56. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003 ; 163 (15). 1849-1856
57. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001 ; 103 (14). 1838-1843
58. Skrupky LP, Smith JR, Deal EN, et al. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia. Pharmacotherapy. 2010 ; 30 (12). 1229-1238
59. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med. 2006 ; 355 (8). 809-817
60. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood. 2000 ; 96 (5). 1703-1708
61. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996 ; 101 (5). 502-507
62. Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood. 2003 ; 101 (1). 31-37
63. Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Br J Haematol. 2006 ; 133 (3). 259-269
64. Zucker-Franklin D, Cao YZ. Megakaryocytes of human immunodeficiency virus-infected individuals express viral RNA. Proc Natl Acad Sci U S A. 1989 ; 86 (14). 5595-5599
65. Zauli G, Catani L, Gibellini D, et al. Impaired survival of bone marrow GPIIb/IIa+ megakaryocytic cells as an additional pathogenetic mechanism of HIV-1-related thrombocytopenia. Br J Haematol. 1996 ; 92 (3). 711-717
66. Thompson GR 3rd, Lawrence VA, Crawford GE. HIV infection increases the risk of heparin-induced thrombocytopenia. Clin Infect Dis. 2007 ; 45 (10). 1393-1396
67. Girard DE, Kumar KL, McAfee JH. Hematologic effects of acute and chronic alcohol abuse. Hematol Oncol Clin North Am. 1987 ; 1 (2). 321-334
68. O'Reilly RA. Splenomegaly in 2,505 patients at a large university medical center from 1913 to 1995. 1963 to 1995: 449 patients. West J Med. 1998 ; 169 (2). 88-97
69. Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest. 1966 ; 45 (5). 645-657
70. Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ. 2007 ; 177 (4). 347-351
71. Savi P, Nurden P, Nurden AT, Levy-Toledano S, Herbert JM. Clopidogrel: a review of its mechanism of action. Platelets. 1998 ; 9 (3-4). 251-255
72. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med. 1998 ; 129 (5). 394-405
73. Marciniak SJ. Mascelli MA, Furman MI, et al. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost. 2002 ; 87 (6). 1020-1025
74. Brown DL, Fann CS, Chang CJ. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention. Am J Cardiol. 2001 ; 87 (5). 537-541
75. Billheimer JT, Dicker IB, Wynn R, et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood. 2002 ; 99 (10). 3540-3546
76. Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis. Am Heart J. 2000 ; 140 (2). 206-211
77. Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost. 2009 ; 7 (6). 911-918
78. Tcheng JE, Kereiakes DJ, Lincoff AM, et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation. 2001 ; 104 (8). 870-875
79. Reese JA, Li X, Hauben M, et al. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood. 2010 ; 116 (12). 2127-2133
80. Pedersen-Bjergaard U, Andersen M, Hansen PB. Drug-specific characteristics of thrombocytopenia caused by non-cytotoxic drugs. Eur J Clin Pharmacol. 1998 ; 54 (9-10). 701-706
81. Wright AJ. The penicillins. Mayo Clin Proc. 1999 ; 74 (3). 290-307
82. ten Berg MJ, Huisman A, Souverein PC, et al. Drug-induced thrombocytopenia: a population study. Drug Saf. 2006 ; 29 (8). 713-721
83. Wilson AP. Comparative safety of teicoplanin and vancomycin. Int J Antimicrob Agents. 1998 ; 10 (2). 143-152
84. Rao N, Ziran BH, Wagener MM, Santa ER, Yu VL. Similar hematologic effects of long-term linezolid and vancomycin therapy in a prospective observational study of patients with orthopedic infections. Clin Infect Dis. 2004 ; 38 (8). 1058-1064
85. Bock M, Muggenthaler KH, Schmidt U, Heim MU. Influence of antibiotics on posttransfusion platelet increment. Transfusion. 1996 ; 36 (11-12). 952-954
86. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002 ; 46 (8). 2723-2726
87. Lin YH, Wu VC, Tsai IJ, et al. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents. 2006 ; 28 (4). 345-351
88. Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006 ; 42 (1). 66-72
89. Wade EE, Rebuck JA, Healey MA, Rogers FB. H(2) antagonist-induced thrombocytopenia: is this a real phenomenon?. Intensive Care Med. 2002 ; 28 (4). 459-465
90. Cawley MJ, Wittbrodt ET, Boyce EG, Skaar DJ. Potential risk factors associated with thrombocytopenia in a surgical intensive care unit. Pharmacotherapy. 1999 ; 19 (1). 108-113
91. Sharma B, Sharma M, Majumder M, Steier W, Sangal A, Kalawar M. Thrombocytopenia in septic shock patients-a prospective observational study of incidence, risk factors and correlation with clinical outcome. Anaesth Intensive Care. 2007 ; 35 (6). 874-880
92. Francois B, Trimoreau F, Vignon P, Fixe P, Praloran V, Gastinne H. Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med. 1997 ; 103 (2). 114-120
93. Mavrommatis AC, Theodoridis T, Orfanidou A, Roussos C, Christopoulou-Kokkinou V, Zakynthinos S. Coagulation system and platelets are fully activated in uncomplicated sepsis. Crit Care Med. 2000 ; 28 (2). 451-457
94. Corrigan JJ, Ray WL, May N. Changes in the blood coagulation system associated with septicemia. N Engl J Med. 1968 ; 279 (16). 851-856
95. Vanderschueren S, De Weerdt A, Malbrain M, et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med. 2000 ; 28 (6). 1871-1876
96. Holzer M, Bernard SA, Hachimi-Idrissi S, Roine RO, Sterz F, Mullner M. Hypothermia for neuroprotection after cardiac arrest: systematic review and individual patient data meta-analysis. Crit Care Med. 2005 ; 33 (2). 414-418
97. Shah PS, Ohlsson A, Perlman M. Hypothermia to treat neonatal hypoxic ischemic encephalopathy: systematic review. Arch Pediatr Adolesc Med. 2007 ; 161 (10). 951-958
98. Hemmen TM, Lyden PD. Induced hypothermia for acute stroke. Stroke. 2007 ; 38 (2 suppl). 794-799
99. Clifton GL, Miller ER, Choi SC, et al. Lack of effect of induction of hypothermia after acute brain injury. N Engl J Med. 2001 ; 344 (8). 556-563
100. Dmello D, Cruz-Flores S, Matuschak GM. Moderate hypothermia with intracranial pressure monitoring as a therapeutic paradigm for the management of acute liver failure: a systematic review. Intensive Care Med. 2010 ; 36 (2). 210-213
101. Seule MA, Muroi C, Mink S, Yonekawa Y, Keller E. Therapeutic hypothermia in patients with aneurysmal subarachnoid hemorrhage, refractory intracranial hypertension, or cerebral vasospasm. Neurosurgery. 2009 ; 64 (1). 86-92
102. Wensel RH, Bigelow WG. The use of heparin to minimize thrombocytopenia and bleeding tendency during hypothermia. Surgery. 1959 ; 45 (2). 223-228
103. Cohen IJ, Amir J, Gedaliah A, Rachmal A, Gorodischer R, Zaizov R. Thrombocytopenia of neonatal cold injury. J Pediatr. 1984 ; 104 (4). 620-622
104. Wyss M, Babel JF, Rouge JC, Bouvier CA. Haemostatic changes during open heart surgery with extracorporeal circulation and deep hypothermia in children. Anaesthesist. 1982 ; 31 (2). 82-86
105. Cohen IJ. Room temperature ADP-induced first-stage hyperaggregation of human platelets: the cause of rewarming deaths by thrombocytopenia in neonatal cold injury. Pediatr Hematol Oncol. 1991 ; 8 (1). 61-67
106. Zhang JN, Wood J, Bergeron AL, et al. Effects of low temperature on shear-induced platelet aggregation and activation. J Trauma. 2004 ; 57 (2). 216-223
107. Slichter SJ, Bolgiano D, Jones MK, et al. Viability and function of 8-day-stored apheresis platelets. Transfusion. 2006 ; 46 (10). 1763-1769
108. Yomtovian R, Lazarus HM, Goodnough LT, Hirschler NV, Morrissey AM, Jacobs MR. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion. 1993 ; 33 (11). 902-909
109. Shanwell A, Diedrich B, Falker C, et al. Paired in vitro and in vivo comparison of apheresis platelet concentrates stored in platelet additive solution for 1 versus 7 days. Transfusion. 2006 ; 46 (6). 973-979
110. Bishop JF, McGrath K, Wolf MM, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood. 1988 ; 71 (2). 383-387
111. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American society of clinical oncology. J Clin Oncol. 2001 ; 19 (5). 1519-1538
112. Liumbruno G, Bennardello F, Lattanzio A, Piccoli P, Rossetti G. Recommendations for the transfusion of plasma and platelets. Blood Transfus. 2009 ; 7 (2). 132-150
113. Slichter SJ. Evidence-based platelet transfusion guidelines. Hematology Am Soc Hematol Educ Program. 2007;2007(1) ;: 172-178
114. Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005 ; 105 (10). 4106-4114
115. Vidarsson B, Onundarson PT. Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost. 2000 ; 83 (4). 634-635